01

Aulos Bioscience to Present Phase 1/2 Imneskibart Data at SITC 2026

Aulos Bioscience will present Phase 1/2 data for imneskibart combined with checkpoint inhibitors in NSCLC and melanoma at SITC 2026, calling results promising.